Monitoring of plasma concentration of imatinib mesylate in patients with chronic myeloid leukemia / 中华血液学杂志
Chinese Journal of Hematology
; (12): 450-453, 2011.
Article
em Zh
| WPRIM
| ID: wpr-251537
Biblioteca responsável:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To analyze the clinical efficacy of imatinib mesylate (IM) for Ph-positive or BCR-ABL positive chronic myeloid leukemia (CML) to couple the trough plasma concentrations (C mins) of IM with clinical responses and adverse events (AEs).</p><p><b>METHODS</b>One hundred and one CML patients received IM therapy, and Cmins of IM were determined in 30 patients.</p><p><b>RESULTS</b>(1) Cumulative complete hematological response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR) and negative BCR/ABL fusion gene rates were 96.6%, 86.5%, 77.5% and 47.2%, respectively, in CML-CP patients. In accelerated and blastic phases (AP and BC) patients, CHR, MCyR, CCyR and negative BCR-ABL fusion gene rates were 58.3%, 25.0%, 25.0%, 8.3%, respectively. (2) Mean Cmins of IM was significantly higher in the CCyR at 1 year [(1472 +/- 482) microg/L] group than in the non-CCyR at 1 years group [(1067 +/- 373) microg/L] (P < 0.05), and higher in the MMR at 1 year group than in the non-MMR at 1 years group [(1624 +/- 468) microg/L vs (1137 +/- 404) microg/L, P < 0.05].</p><p><b>CONCLUSION</b>IM significantly improves cytogenetic and molecular response, event-free survival, and overall survival for patients with Ph-positive CML. The Cmins of IM exerts a significant impact on clinical response (CCyR and MMR at 1 year).</p>
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Piperazinas
/
Pirimidinas
/
Benzamidas
/
Sangue
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Resultado do Tratamento
/
Usos Terapêuticos
/
Tratamento Farmacológico
/
Mesilato de Imatinib
/
Antineoplásicos
Limite:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
Idioma:
Zh
Revista:
Chinese Journal of Hematology
Ano de publicação:
2011
Tipo de documento:
Article